Marisa Wexler, MS, senior science writer —

Synairgen‘s anti-viral therapy SNG001 has a good safety profile in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show. The data also indicate that SNG001 induces its intended anti-viral effect, and that it improves lung function in COPD patients with viral lung infections. “These…

Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) outperformed Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe exacerbations in people with chronic obstructive pulmonary disease (COPD) during all seasons of the year, new data from the ETHOS clinical trial show. That data will be presented by…

AstraZeneca‘s Breztri Aerosphere has been approved by the U.S. Food and Drug Administration (FDA) as a maintenance treatment for chronic obstructive pulmonary disease (COPD). Formerly known as PT010, Breztri Aerosphere is an inhaled therapy with three active components: the long-acting muscarinic antagonist…

The ProAir Digihaler, a digital inhaler designed for people with asthma and chronic obstructive pulmonary disease (COPD) to monitor their inhaler usage through the use of a mobile app, is now available by prescription in the U.S. The albuterol inhaler (albuterol sulfate, 117 micrograms), developed by Teva…

Nuvaira‘s Lung Denervation System, under clinical investigation for its use in treating chronic obstructive pulmonary disease (COPD), has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). This designation is given to devices that have the potential to substantially improve the…

Following a stop due to the COVID-19 pandemic, the Medical University of South Carolina (MUSC) has become the first medical center to restart the AIRFLOW-3 clinical trial, which is testing a procedure called targeted lung denervation as a potential therapy for chronic obstructive pulmonary disease (COPD). “We’re…

People with chronic obstructive pulmonary disease (COPD) who are overweight have increased levels of the protein that the SARS-CoV-2 virus — the virus that causes COVID-19 — uses to get into cells, a new study shows. The results suggest that these individuals may be at greater risk of contracting…

Pulmonx’s  Zephyr Endobronchial Valve significantly reduces breathlessness and improves physical activity and quality of life in people with severe emphysema, a post-hoc analysis of clinical trial data shows. The study, “Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels and Quality of Life at One…

Triple therapy with fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) can reduce mortality rates among people with chronic obstructive pulmonary disease (COPD) more than VI treatment with either FF or UMEC, a new analysis of trial data suggests. The findings were published in the American…

New official guidelines have been published by the American Thoracic Society (ATS) for the treatment of chronic obstructive pulmonary disease (COPD). Among the new recommendations, the combination of long-acting beta two agonists (LABA) and long-acting muscarinic antagonists (LAMA) is recommended over either therapy alone to treat people with COPD…